((自动化翻译由路透提供，请见免责声明 ))
10月7日 - ** 药物开发商Halozyme Therapeutics 股价下跌2.5%至57.70美元
** 富国银行将其股票评级从 "增持 "下调至 "等权重"
** 不过，券商将预测价格从58美元上调至62美元，与该股上次收盘价相比，有~5%的上涨空间
** 券商称，光环公司即将推出的产品线是持有该股的一个理由，但共识数据已经考虑了这些因素。
** 11位跟踪光环公司的分析师的平均评级为 "买入"；他们的预测中值为64美元--LSEG
** 截至上次收盘，该股今年累计上涨约 60%，而纳斯达克生物技术指数 上涨约 8
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.